Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc., retaining the price target of $36.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sam Slutsky’s rating is based on ArriVent BioPharma, Inc.’s promising developments in their treatment pipeline, particularly in the area of EGFR exon 20 mutant non-small cell lung cancer (NSCLC). The company’s lead candidate, firmonertinib, is a selective, brain-penetrant EGFR-TKI, which shows potential in addressing unmet medical needs in this patient population.
Additionally, the competitive landscape highlights ArriVent’s strategic positioning, as the data from Oric Pharmaceuticals’ competing product, enozertinib, underscores the importance of effective treatments for EGFR exon 20 mutations. The positive clinical data and ArriVent’s focus on innovative solutions contribute to the Buy rating, reflecting confidence in the company’s future growth prospects.
Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Cogent Biosciences, and Olema Pharmaceuticals. According to TipRanks, Slutsky has an average return of 39.4% and a 51.63% success rate on recommended stocks.